ERGOTAMINE TARTRATE AND CAFFEINE

Post-LOE

Hikma

ANDAORALTABLET

Approved

Sep 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

ERGOTAMINE TARTRATE AND CAFFEINE by Hikma is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. First approved in 2004.

Drug data last refreshed Yesterday

Mechanism of Action

CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Worked on ERGOTAMINE TARTRATE AND CAFFEINE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.